21-hydroxylase deficiency natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Aditya Ganti (talk | contribs) |
||
| (15 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{21-hydroxylase deficiency}} | ||
{{CMG}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
Common complications of | If left untreated, patients with [[21-hydroxylase]] deficiency may progress to develop [[complications]]. Common [[complications]] of [[21-Hydroxylase|21-hydroxylase]] deficient [[congenital adrenal hyperplasia]] include [[short stature]], [[adrenal crisis]], [[infertility]], and [[precocious puberty]]. The [[prognosis]] of 21-hydroxylase deficiency is generally good with treatment. | ||
==Natural History== | |||
* If left untreated, patients with 21-hydroxylase deficiency may progress to develop complications. | |||
* [[Androgen]] excess in childhood leads to pseudoprecocious [[puberty]], accelerated childhood growth with [[premature]] [[epiphyseal]] closure, which causes an overall [[short stature]], and various [[metabolic]] abnormalities. | |||
* [[Adult|Adults]] may also face [[fertility]] issues, both in classic and non-classic forms of [[21-hydroxylase]] deficiency. | |||
* [[Testicular]] [[adrenal]] rest [[tumors]] (nodular [[hyperplasia]] arising from [[cells]] that have many characteristics of [[adrenocortical]] [[cells]] and migrated with the [[testis]] during [[fetal]] development) may also occur and patients with 21-hydroxylase deficiency require monitoring for these [[tumors]]. These [[tumors]] indicate poor disease control and are usually reversible with optimum treatment.<ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref><ref name="pmid15554889">{{cite journal |vauthors=van der Kamp HJ, Wit JM |title=Neonatal screening for congenital adrenal hyperplasia |journal=Eur. J. Endocrinol. |volume=151 Suppl 3 |issue= |pages=U71–5 |year=2004 |pmid=15554889 |doi= |url=}}</ref> | |||
==Complications== | ==Complications== | ||
Common complications associated with 21-hydroxylase | Common complications associated with [[21-hydroxylase]] deficiency include:<ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref><ref name="pmid15554889">{{cite journal |vauthors=van der Kamp HJ, Wit JM |title=Neonatal screening for congenital adrenal hyperplasia |journal=Eur. J. Endocrinol. |volume=151 Suppl 3 |issue= |pages=U71–5 |year=2004 |pmid=15554889 |doi= |url=}}</ref> | ||
*[[Adrenal crisis]] | *[[Adrenal crisis]] | ||
*[[Infertility]] | *[[Infertility]] | ||
| Line 16: | Line 22: | ||
==Prognosis== | ==Prognosis== | ||
*The prognosis of | *The [[prognosis]] of 21-hydroxylase deficiency is generally good with treatment. | ||
* A small percentage of children and adults with [[infancy]] or [[childhood]] onset 21 hydroxylase deficiency die of [[adrenal crisis]], even after diagnosis and initiation of treatment. | |||
* There may be no immediate worsening of [[symptoms]] if a person is well and has missed a dose or even several doses. However, [[glucocorticoid]] needs are increased during illness and stress. | |||
* Missed doses during time of illness can lead (within hours) to [[hypotension]], [[Shock (medical)|shock]], and death.<ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref><ref name="pmid15554889">{{cite journal |vauthors=van der Kamp HJ, Wit JM |title=Neonatal screening for congenital adrenal hyperplasia |journal=Eur. J. Endocrinol. |volume=151 Suppl 3 |issue= |pages=U71–5 |year=2004 |pmid=15554889 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | |||
[[Category:Pediatrics]] | |||
[[Category:Endocrinology]] | |||
[[Category:Genetic disorders]] | |||
[[Category:Intersexuality]] | |||
[[Category:Medicine]] | |||
[[Category: Up-To-Date]] | |||
Latest revision as of 15:36, 24 July 2020
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency natural history, complications and prognosis |
|
FDA on 21-hydroxylase deficiency natural history, complications and prognosis |
|
CDC on 21-hydroxylase deficiency natural history, complications and prognosis |
|
21-hydroxylase deficiency natural history, complications and prognosis in the news |
|
Blogs on 21-hydroxylase deficiency natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
If left untreated, patients with 21-hydroxylase deficiency may progress to develop complications. Common complications of 21-hydroxylase deficient congenital adrenal hyperplasia include short stature, adrenal crisis, infertility, and precocious puberty. The prognosis of 21-hydroxylase deficiency is generally good with treatment.
Natural History
- If left untreated, patients with 21-hydroxylase deficiency may progress to develop complications.
- Androgen excess in childhood leads to pseudoprecocious puberty, accelerated childhood growth with premature epiphyseal closure, which causes an overall short stature, and various metabolic abnormalities.
- Adults may also face fertility issues, both in classic and non-classic forms of 21-hydroxylase deficiency.
- Testicular adrenal rest tumors (nodular hyperplasia arising from cells that have many characteristics of adrenocortical cells and migrated with the testis during fetal development) may also occur and patients with 21-hydroxylase deficiency require monitoring for these tumors. These tumors indicate poor disease control and are usually reversible with optimum treatment.[1][2]
Complications
Common complications associated with 21-hydroxylase deficiency include:[1][2]
Prognosis
- The prognosis of 21-hydroxylase deficiency is generally good with treatment.
- A small percentage of children and adults with infancy or childhood onset 21 hydroxylase deficiency die of adrenal crisis, even after diagnosis and initiation of treatment.
- There may be no immediate worsening of symptoms if a person is well and has missed a dose or even several doses. However, glucocorticoid needs are increased during illness and stress.
- Missed doses during time of illness can lead (within hours) to hypotension, shock, and death.[1][2]
References
- ↑ 1.0 1.1 1.2 Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.
- ↑ 2.0 2.1 2.2 van der Kamp HJ, Wit JM (2004). "Neonatal screening for congenital adrenal hyperplasia". Eur. J. Endocrinol. 151 Suppl 3: U71–5. PMID 15554889.